SV Health Investors

Imbria Pharmaceuticals, founded in 2018 and headquartered in Boston, Massachusetts, is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies targeting cardiometabolic disorders. The company focuses on understanding the underlying mechanisms of these diseases, particularly energetic impairment at the cellular level, to inform its therapeutic candidates. Imbria's pipeline aims to improve the lives of patients suffering from conditions such as non-obstructive hypertrophic cardiomyopathy, stable angina, and heart failure with preserved ejection fraction by restoring or enhancing cellular energy production.

SpectraWAVE, Inc. is a medical device company based in Waltham, Massachusetts, founded in 2017. The company specializes in the development and manufacturing of optical diagnostic and therapeutic devices aimed at enhancing the diagnosis and treatment of cardiovascular diseases. Its flagship product includes a spectroscopy catheter that assists in diagnosing and treating cardiovascular conditions. SpectraWAVE has also developed an advanced intravascular imaging technology that integrates proven imaging methodologies to improve outcomes for coronary artery disease. This technology provides interventional cardiologists with critical optical and computational insights to optimize stent interventions and identify patients and plaques at risk of adverse coronary events, ultimately aiming to improve patient treatment and outcomes in the field of cardiovascular health.

CSA Medical, Inc., established in 1993 and headquartered in Baltimore, Maryland, specializes in the development and manufacturing of spray cryotherapy medical devices. Its primary product, truFreeze, utilizes cold liquid nitrogen to destroy unwanted tissue across dermatology, gynecology, and general surgery fields while promoting healthy tissue regrowth. CSA Medical also offers the Rapid AV Spray Kit to enhance truFreeze's efficiency. The company operates a research and development facility in Lexington, Massachusetts.

Miach Orthopaedics is a medical device company based in Westborough, Massachusetts, specializing in the development of bio-engineered surgical implants aimed at promoting new tissue growth and aiding in connective tissue repair. Founded in 2016, the company focuses on its innovative Bridge-Enhanced ACL Repair technology, which serves as an alternative to traditional anterior cruciate ligament (ACL) reconstruction. This technology provides surgeons with a method to restore the normal anatomy and function of the knee for patients who have experienced ACL injuries, offering a promising option for recovery and rehabilitation.

Nimbus Therapeutics, LLC is a biotechnology company based in Cambridge, Massachusetts, focused on discovering and developing innovative medicines for serious diseases, including metabolic disorders, cancer, and immune-inflammatory conditions. Founded in 2009, the company utilizes a computational technology-driven approach to advance a pipeline of novel small-molecule therapeutics. Nimbus Therapeutics specializes in designing allosteric inhibitors, notably targeting Acetyl-CoA Carboxylase for conditions such as non-alcoholic steatohepatitis and hepatocellular carcinoma. The company has established strategic partnerships with organizations like Charles River Laboratories and Celgene Corporation to enhance its drug development efforts. In March 2015, Nimbus Discovery rebranded itself as Nimbus Therapeutics to better reflect its transition into a clinical-stage enterprise.

Nimbus Therapeutics, LLC is a biotechnology company based in Cambridge, Massachusetts, focused on discovering and developing innovative medicines for serious diseases, including metabolic disorders, cancer, and immune-inflammatory conditions. Founded in 2009, the company utilizes a computational technology-driven approach to advance a pipeline of novel small-molecule therapeutics. Nimbus Therapeutics specializes in designing allosteric inhibitors, notably targeting Acetyl-CoA Carboxylase for conditions such as non-alcoholic steatohepatitis and hepatocellular carcinoma. The company has established strategic partnerships with organizations like Charles River Laboratories and Celgene Corporation to enhance its drug development efforts. In March 2015, Nimbus Discovery rebranded itself as Nimbus Therapeutics to better reflect its transition into a clinical-stage enterprise.

Xilio Therapeutics is a clinical-stage biotechnology company focused on developing innovative immunotherapies to enhance the immune system's ability to combat cancer. The company specializes in tumor-selective immunotherapies, utilizing its proprietary technology to maximize the effectiveness of immuno-oncology treatments while minimizing side effects outside the tumor. Among its key products is XTX201, which aims to induce immune activity directly within tumors, demonstrating improved antitumor effects. Founded in 2015 and based in Waltham, Massachusetts, Xilio Therapeutics was previously known as Akrevia Therapeutics until its rebranding in March 2020. The company is dedicated to advancing a pipeline of novel immuno-oncology molecules, including tumor-activated cytokines and antibodies, with the goal of significantly improving patient outcomes in cancer treatment.

Catamaran Bio, Inc. is a biotechnology company focused on developing allogeneic CAR-NK immune cell therapies for the treatment of solid tumors and other cancers. Founded in 2019 and based in Cambridge, Massachusetts, the company utilizes its Tailwind platform to engineer, expand, and process natural killer (NK) cells into off-the-shelf CAR-NK cell therapy products. By leveraging genetic engineering, Catamaran Bio aims to address significant unmet medical needs in cancer treatment, providing transformative therapies for patients.

Amwell is a telehealth platform based in the United States that facilitates the digital delivery of healthcare services. Founded in 2006 and headquartered in Boston, the company connects providers, insurers, patients, and innovators to enhance access to affordable, high-quality care. Amwell offers a comprehensive platform designed to address a wide range of telehealth needs, including urgent, acute, and post-acute care, as well as chronic care management and healthy living. With extensive experience in the field, Amwell supports over 240 health systems, which encompass 2,000 hospitals, and collaborates with 55 health plan partners, reaching more than 150 million individuals through over 36,000 employers. The platform provides both on-demand and scheduled consultations, enabling diverse care models that range from primary and urgent care to specialized services such as telestroke and telepsychiatry.

Xilio Therapeutics is a clinical-stage biotechnology company focused on developing innovative immunotherapies to enhance the immune system's ability to combat cancer. The company specializes in tumor-selective immunotherapies, utilizing its proprietary technology to maximize the effectiveness of immuno-oncology treatments while minimizing side effects outside the tumor. Among its key products is XTX201, which aims to induce immune activity directly within tumors, demonstrating improved antitumor effects. Founded in 2015 and based in Waltham, Massachusetts, Xilio Therapeutics was previously known as Akrevia Therapeutics until its rebranding in March 2020. The company is dedicated to advancing a pipeline of novel immuno-oncology molecules, including tumor-activated cytokines and antibodies, with the goal of significantly improving patient outcomes in cancer treatment.

Caraway Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, that focuses on developing innovative treatments for neurodegenerative diseases by modulating mitophagy and autophagy. The company aims to address the degradation of toxic cellular components, which is a key factor in various neurodegenerative conditions, including Parkinson's disease and amyotrophic lateral sclerosis. By leveraging an understanding of critical neural pathways, Caraway Therapeutics seeks to discover and develop novel small molecules that can restore cellular balance and improve lysosomal function. Founded in 2018 and initially known as Rheostat Therapeutics, Inc., the company rebranded in 2019 to reflect its commitment to finding effective therapies for patients affected by these debilitating diseases.

CSA Medical, Inc., established in 1993 and headquartered in Baltimore, Maryland, specializes in the development and manufacturing of spray cryotherapy medical devices. Its primary product, truFreeze, utilizes cold liquid nitrogen to destroy unwanted tissue across dermatology, gynecology, and general surgery fields while promoting healthy tissue regrowth. CSA Medical also offers the Rapid AV Spray Kit to enhance truFreeze's efficiency. The company operates a research and development facility in Lexington, Massachusetts.

Caraway Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, that focuses on developing innovative treatments for neurodegenerative diseases by modulating mitophagy and autophagy. The company aims to address the degradation of toxic cellular components, which is a key factor in various neurodegenerative conditions, including Parkinson's disease and amyotrophic lateral sclerosis. By leveraging an understanding of critical neural pathways, Caraway Therapeutics seeks to discover and develop novel small molecules that can restore cellular balance and improve lysosomal function. Founded in 2018 and initially known as Rheostat Therapeutics, Inc., the company rebranded in 2019 to reflect its commitment to finding effective therapies for patients affected by these debilitating diseases.

Ribometrix, Inc. is a biotechnology company founded in 2014 and headquartered in Durham, North Carolina. The company specializes in discovering and developing small molecule drugs that target functional three-dimensional RNA structures, aiming to address various human diseases. Ribometrix employs advanced techniques in RNA structural analysis, utilizing proprietary methods and state-of-the-art tools, including artificial intelligence and machine learning, to identify novel small molecules that can inhibit the production of disease-associated proteins. By focusing on RNA biology, Ribometrix seeks to lead a new paradigm in small molecule therapeutics, enhancing the understanding and modulation of RNA's role in disease mechanisms.

Xilio Therapeutics is a clinical-stage biotechnology company focused on developing innovative immunotherapies to enhance the immune system's ability to combat cancer. The company specializes in tumor-selective immunotherapies, utilizing its proprietary technology to maximize the effectiveness of immuno-oncology treatments while minimizing side effects outside the tumor. Among its key products is XTX201, which aims to induce immune activity directly within tumors, demonstrating improved antitumor effects. Founded in 2015 and based in Waltham, Massachusetts, Xilio Therapeutics was previously known as Akrevia Therapeutics until its rebranding in March 2020. The company is dedicated to advancing a pipeline of novel immuno-oncology molecules, including tumor-activated cytokines and antibodies, with the goal of significantly improving patient outcomes in cancer treatment.

Ribometrix, Inc. is a biotechnology company founded in 2014 and headquartered in Durham, North Carolina. The company specializes in discovering and developing small molecule drugs that target functional three-dimensional RNA structures, aiming to address various human diseases. Ribometrix employs advanced techniques in RNA structural analysis, utilizing proprietary methods and state-of-the-art tools, including artificial intelligence and machine learning, to identify novel small molecules that can inhibit the production of disease-associated proteins. By focusing on RNA biology, Ribometrix seeks to lead a new paradigm in small molecule therapeutics, enhancing the understanding and modulation of RNA's role in disease mechanisms.

Cerevance LLC is a biotechnology company focused on developing innovative therapeutics for neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, frontotemporal dementia, and amyotrophic lateral sclerosis. Founded in 2016 and headquartered in Boston, Massachusetts, with a branch in Cambridge, United Kingdom, Cerevance utilizes its NETSseq platform to profile specific brain cell types, including neurons and glial cells, within mature human brain tissue. By leveraging a substantial repository of over 15,000 human brain samples, the company generates extensive expression and epigenetic data, guiding the identification of promising therapeutic targets. This approach aims to address the early onset of central nervous system diseases by revealing critical transcriptional and epigenetic differences within affected brain regions.

Arsanis, Inc. is a clinical-stage biopharmaceutical company headquartered in Waltham, Massachusetts, specializing in monoclonal antibody (mAb) immunotherapies for serious infectious diseases. Founded in 2010, Arsanis focuses on developing innovative therapies targeting various bacterial and viral pathogens. Its lead clinical program, ASN100, is currently in a Phase 2 trial aimed at preventing Staphylococcus aureus pneumonia in high-risk, mechanically ventilated patients. The company's preclinical pipeline includes mAbs directed against respiratory syncytial virus and Gram-negative bacteria, such as Klebsiella pneumoniae and Escherichia coli. Arsanis leverages advanced mAb discovery techniques to create a diverse range of therapeutic candidates with multiple mechanisms of action, addressing the urgent need for effective treatments in infectious disease management. The company also has research and preclinical development operations in Vienna, Austria, under Arsanis Biosciences GmbH.

Good Start Genetics, Inc. is a molecular diagnostics company based in Cambridge, Massachusetts, founded in 2007. It specializes in genetic screening for inherited diseases, aiming to transform reproductive medicine by providing actionable information to physicians and patients. The company offers a range of services, including EmbryVu, a preimplantation genetic screening test designed to enhance in vitro fertilization outcomes by identifying suitable embryos for implantation. Additionally, Good Start Genetics provides a comprehensive array of genetic carrier screening tests through its GoodStart Select program, utilizing advanced next-generation DNA sequencing technology along with other established genetic screening methods. This focus on high carrier detection rates and commitment to customer care and genetic counseling positions the company as a leader in the field of pre-pregnancy genetic testing and diagnostics. As of August 2017, Good Start Genetics operates as a subsidiary of Invitae Corporation.

NKT Therapeutics, Inc. is a biotechnology company based in Waltham, Massachusetts, that specializes in developing therapeutics based on natural killer T (NKT) cells. Established in 2008, the company focuses on creating a pipeline of first-in-class NKT-based treatments targeting a range of conditions, including sickle cell disease, autoimmune and inflammatory diseases, cancer, asthma, and dermatitis. NKT Therapeutics utilizes a unique biotechnology platform that offers humanized monoclonal antibodies to selectively deplete iNKT cells, which are implicated in organ damage in preclinical models of sickle cell disease. By leveraging its expertise in the intersection of innate and adaptive immunity, NKT Therapeutics aims to provide innovative solutions for complex health challenges.

CSA Medical, Inc., established in 1993 and headquartered in Baltimore, Maryland, specializes in the development and manufacturing of spray cryotherapy medical devices. Its primary product, truFreeze, utilizes cold liquid nitrogen to destroy unwanted tissue across dermatology, gynecology, and general surgery fields while promoting healthy tissue regrowth. CSA Medical also offers the Rapid AV Spray Kit to enhance truFreeze's efficiency. The company operates a research and development facility in Lexington, Massachusetts.

CardioFocus, Inc. is a biotechnology company specializing in the development of innovative medical devices for the treatment of cardiac disorders, particularly atrial fibrillation. Founded in 1990 and headquartered in Marlborough, Massachusetts, the company has created advanced endoscopic ablation systems that enhance precision and control during medical procedures. Its flagship product, the HeartLight Endoscopic Ablation System, utilizes laser balloon technology to achieve consistent pulmonary vein isolation, crucial for managing paroxysmal atrial fibrillation. Additionally, the HeartLight Excalibur Balloon offers clinicians the ability to maintain stable contact with direct visualization for effective lesion creation, while the HeartLight X3 System provides a mode for controlled lesion development. CardioFocus aims to equip electrophysiologists with tools that improve treatment outcomes through enhanced visualization and customizable energy delivery, addressing the specific needs of patients undergoing ablation procedures.

Good Start Genetics, Inc. is a molecular diagnostics company based in Cambridge, Massachusetts, founded in 2007. It specializes in genetic screening for inherited diseases, aiming to transform reproductive medicine by providing actionable information to physicians and patients. The company offers a range of services, including EmbryVu, a preimplantation genetic screening test designed to enhance in vitro fertilization outcomes by identifying suitable embryos for implantation. Additionally, Good Start Genetics provides a comprehensive array of genetic carrier screening tests through its GoodStart Select program, utilizing advanced next-generation DNA sequencing technology along with other established genetic screening methods. This focus on high carrier detection rates and commitment to customer care and genetic counseling positions the company as a leader in the field of pre-pregnancy genetic testing and diagnostics. As of August 2017, Good Start Genetics operates as a subsidiary of Invitae Corporation.

CardioFocus, Inc. is a biotechnology company specializing in the development of innovative medical devices for the treatment of cardiac disorders, particularly atrial fibrillation. Founded in 1990 and headquartered in Marlborough, Massachusetts, the company has created advanced endoscopic ablation systems that enhance precision and control during medical procedures. Its flagship product, the HeartLight Endoscopic Ablation System, utilizes laser balloon technology to achieve consistent pulmonary vein isolation, crucial for managing paroxysmal atrial fibrillation. Additionally, the HeartLight Excalibur Balloon offers clinicians the ability to maintain stable contact with direct visualization for effective lesion creation, while the HeartLight X3 System provides a mode for controlled lesion development. CardioFocus aims to equip electrophysiologists with tools that improve treatment outcomes through enhanced visualization and customizable energy delivery, addressing the specific needs of patients undergoing ablation procedures.

Arsanis, Inc. is a clinical-stage biopharmaceutical company headquartered in Waltham, Massachusetts, specializing in monoclonal antibody (mAb) immunotherapies for serious infectious diseases. Founded in 2010, Arsanis focuses on developing innovative therapies targeting various bacterial and viral pathogens. Its lead clinical program, ASN100, is currently in a Phase 2 trial aimed at preventing Staphylococcus aureus pneumonia in high-risk, mechanically ventilated patients. The company's preclinical pipeline includes mAbs directed against respiratory syncytial virus and Gram-negative bacteria, such as Klebsiella pneumoniae and Escherichia coli. Arsanis leverages advanced mAb discovery techniques to create a diverse range of therapeutic candidates with multiple mechanisms of action, addressing the urgent need for effective treatments in infectious disease management. The company also has research and preclinical development operations in Vienna, Austria, under Arsanis Biosciences GmbH.

Arsanis, Inc. is a clinical-stage biopharmaceutical company headquartered in Waltham, Massachusetts, specializing in monoclonal antibody (mAb) immunotherapies for serious infectious diseases. Founded in 2010, Arsanis focuses on developing innovative therapies targeting various bacterial and viral pathogens. Its lead clinical program, ASN100, is currently in a Phase 2 trial aimed at preventing Staphylococcus aureus pneumonia in high-risk, mechanically ventilated patients. The company's preclinical pipeline includes mAbs directed against respiratory syncytial virus and Gram-negative bacteria, such as Klebsiella pneumoniae and Escherichia coli. Arsanis leverages advanced mAb discovery techniques to create a diverse range of therapeutic candidates with multiple mechanisms of action, addressing the urgent need for effective treatments in infectious disease management. The company also has research and preclinical development operations in Vienna, Austria, under Arsanis Biosciences GmbH.

Good Start Genetics, Inc. is a molecular diagnostics company based in Cambridge, Massachusetts, founded in 2007. It specializes in genetic screening for inherited diseases, aiming to transform reproductive medicine by providing actionable information to physicians and patients. The company offers a range of services, including EmbryVu, a preimplantation genetic screening test designed to enhance in vitro fertilization outcomes by identifying suitable embryos for implantation. Additionally, Good Start Genetics provides a comprehensive array of genetic carrier screening tests through its GoodStart Select program, utilizing advanced next-generation DNA sequencing technology along with other established genetic screening methods. This focus on high carrier detection rates and commitment to customer care and genetic counseling positions the company as a leader in the field of pre-pregnancy genetic testing and diagnostics. As of August 2017, Good Start Genetics operates as a subsidiary of Invitae Corporation.

Soffio Medical, Inc. is a Boston-based company focused on developing innovative medical devices for respiratory diseases. The firm specializes in implantable technologies that aim to address chronic obstructive pulmonary disease (COPD) and similar conditions. Its devices are designed to implement an airway bypass concept, allowing for the venting of trapped air from areas distal to high-resistance airways. This approach helps reduce residual lung volume and alleviates symptoms associated with respiratory diseases, ultimately enhancing the quality of life for patients.

Deciphera Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, focused on developing innovative treatments for cancer. The company aims to improve the lives of cancer patients by addressing mechanisms of drug resistance that hinder effective therapy responses. Its lead candidate, ripretinib, is specifically designed for gastrointestinal stromal tumors and is undergoing trials for various other cancers, including gliomas and melanoma. Additionally, Deciphera is advancing other clinical-stage candidates, such as DCC-3014, targeting tenosynovial giant cell tumors, and Rebastinib, which is being explored in combination with chemotherapy for solid tumors. The company also has a preclinical candidate, DCC-3116, aimed at treating RAS mutant cancers. Deciphera leverages its proprietary switch-control kinase inhibitor platform and has received regulatory approvals for its lead product in several countries, enhancing its commitment to developing vital cancer therapies.

KalVista Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet medical needs. The company's primary focus is on plasma kallikrein inhibitors aimed at treating hereditary angioedema (HAE) and diabetic macular edema (DME), which is a leading cause of vision loss in adults. KalVista's product pipeline includes KVD001, KVD900, and KVD824, which are designed to provide innovative therapeutic options for patients who may not respond adequately to existing treatments. The company also has a preclinical program exploring a novel oral Factor XIIa inhibitor. With over two decades of expertise in serine protease inhibitor research, KalVista is positioned to address critical gaps in treatment for these conditions.

CardioFocus, Inc. is a biotechnology company specializing in the development of innovative medical devices for the treatment of cardiac disorders, particularly atrial fibrillation. Founded in 1990 and headquartered in Marlborough, Massachusetts, the company has created advanced endoscopic ablation systems that enhance precision and control during medical procedures. Its flagship product, the HeartLight Endoscopic Ablation System, utilizes laser balloon technology to achieve consistent pulmonary vein isolation, crucial for managing paroxysmal atrial fibrillation. Additionally, the HeartLight Excalibur Balloon offers clinicians the ability to maintain stable contact with direct visualization for effective lesion creation, while the HeartLight X3 System provides a mode for controlled lesion development. CardioFocus aims to equip electrophysiologists with tools that improve treatment outcomes through enhanced visualization and customizable energy delivery, addressing the specific needs of patients undergoing ablation procedures.

X4 Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of innovative therapeutics for primary immune deficiencies and cancer. The company's lead drug candidate, mavorixafor, is an oral small molecule antagonist of the chemokine receptor CXCR4, currently undergoing multiple clinical trials. These include a Phase III trial for patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome, as well as Phase Ib and Phase IIa trials focused on severe congenital neutropenia and clear cell renal cell carcinoma, respectively. In addition, X4 Pharmaceuticals is advancing X4P-002, targeting glioblastoma multiforme, and X4P-003 aimed at primary immune deficiencies. The company has also established a license agreement with Abbisko Therapeutics to develop mavorixafor in combination with checkpoint inhibitors for oncology applications. Founded in 2014, X4 Pharmaceuticals was previously known as Arsanis, Inc. before rebranding in March 2019.

CSA Medical, Inc., established in 1993 and headquartered in Baltimore, Maryland, specializes in the development and manufacturing of spray cryotherapy medical devices. Its primary product, truFreeze, utilizes cold liquid nitrogen to destroy unwanted tissue across dermatology, gynecology, and general surgery fields while promoting healthy tissue regrowth. CSA Medical also offers the Rapid AV Spray Kit to enhance truFreeze's efficiency. The company operates a research and development facility in Lexington, Massachusetts.

Soffio Medical, Inc. is a Boston-based company focused on developing innovative medical devices for respiratory diseases. The firm specializes in implantable technologies that aim to address chronic obstructive pulmonary disease (COPD) and similar conditions. Its devices are designed to implement an airway bypass concept, allowing for the venting of trapped air from areas distal to high-resistance airways. This approach helps reduce residual lung volume and alleviates symptoms associated with respiratory diseases, ultimately enhancing the quality of life for patients.

Astria Therapeutics is a biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing innovative therapies for patients affected by rare allergic and immunological diseases. The company focuses on creating life-changing treatments, with its lead program, STAR-0215, being a monoclonal antibody designed to inhibit plasma kallikrein, currently in preclinical development for hereditary angioedema. Additionally, Astria is advancing STAR-0310, another monoclonal antibody, which targets the OX40 receptor and is also in preclinical development for atopic dermatitis, a condition characterized by impaired skin barrier function and significant itching. Through its targeted approach, Astria Therapeutics aims to address unmet medical needs in the field of immunology.

Arsanis, Inc. is a clinical-stage biopharmaceutical company headquartered in Waltham, Massachusetts, specializing in monoclonal antibody (mAb) immunotherapies for serious infectious diseases. Founded in 2010, Arsanis focuses on developing innovative therapies targeting various bacterial and viral pathogens. Its lead clinical program, ASN100, is currently in a Phase 2 trial aimed at preventing Staphylococcus aureus pneumonia in high-risk, mechanically ventilated patients. The company's preclinical pipeline includes mAbs directed against respiratory syncytial virus and Gram-negative bacteria, such as Klebsiella pneumoniae and Escherichia coli. Arsanis leverages advanced mAb discovery techniques to create a diverse range of therapeutic candidates with multiple mechanisms of action, addressing the urgent need for effective treatments in infectious disease management. The company also has research and preclinical development operations in Vienna, Austria, under Arsanis Biosciences GmbH.

Astria Therapeutics is a biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing innovative therapies for patients affected by rare allergic and immunological diseases. The company focuses on creating life-changing treatments, with its lead program, STAR-0215, being a monoclonal antibody designed to inhibit plasma kallikrein, currently in preclinical development for hereditary angioedema. Additionally, Astria is advancing STAR-0310, another monoclonal antibody, which targets the OX40 receptor and is also in preclinical development for atopic dermatitis, a condition characterized by impaired skin barrier function and significant itching. Through its targeted approach, Astria Therapeutics aims to address unmet medical needs in the field of immunology.

Good Start Genetics, Inc. is a molecular diagnostics company based in Cambridge, Massachusetts, founded in 2007. It specializes in genetic screening for inherited diseases, aiming to transform reproductive medicine by providing actionable information to physicians and patients. The company offers a range of services, including EmbryVu, a preimplantation genetic screening test designed to enhance in vitro fertilization outcomes by identifying suitable embryos for implantation. Additionally, Good Start Genetics provides a comprehensive array of genetic carrier screening tests through its GoodStart Select program, utilizing advanced next-generation DNA sequencing technology along with other established genetic screening methods. This focus on high carrier detection rates and commitment to customer care and genetic counseling positions the company as a leader in the field of pre-pregnancy genetic testing and diagnostics. As of August 2017, Good Start Genetics operates as a subsidiary of Invitae Corporation.

AlloCure, Inc. is a biotechnology company focused on developing cell therapies for kidney diseases and related conditions, including organ transplants and multi-organ injuries. Founded in 2006 and based in Burlington, Massachusetts, with additional operations in Salt Lake City, Utah, and Hamburg, Germany, AlloCure is dedicated to creating off-the-shelf biological therapies to address serious health issues affecting millions globally. The company's lead product, AC607, is a biologic therapy currently in development for acute kidney injury, with potential applications for other critical illnesses. AlloCure leverages proprietary technology utilizing processed cells derived from human bone marrow, founded by esteemed scientists Dr. Christof Westenfelder and Dr. Axel Zander, who have significant expertise in developing effective treatments for kidney diseases.

CSA Medical, Inc., established in 1993 and headquartered in Baltimore, Maryland, specializes in the development and manufacturing of spray cryotherapy medical devices. Its primary product, truFreeze, utilizes cold liquid nitrogen to destroy unwanted tissue across dermatology, gynecology, and general surgery fields while promoting healthy tissue regrowth. CSA Medical also offers the Rapid AV Spray Kit to enhance truFreeze's efficiency. The company operates a research and development facility in Lexington, Massachusetts.

Astria Therapeutics is a biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing innovative therapies for patients affected by rare allergic and immunological diseases. The company focuses on creating life-changing treatments, with its lead program, STAR-0215, being a monoclonal antibody designed to inhibit plasma kallikrein, currently in preclinical development for hereditary angioedema. Additionally, Astria is advancing STAR-0310, another monoclonal antibody, which targets the OX40 receptor and is also in preclinical development for atopic dermatitis, a condition characterized by impaired skin barrier function and significant itching. Through its targeted approach, Astria Therapeutics aims to address unmet medical needs in the field of immunology.

KalVista Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet medical needs. The company's primary focus is on plasma kallikrein inhibitors aimed at treating hereditary angioedema (HAE) and diabetic macular edema (DME), which is a leading cause of vision loss in adults. KalVista's product pipeline includes KVD001, KVD900, and KVD824, which are designed to provide innovative therapeutic options for patients who may not respond adequately to existing treatments. The company also has a preclinical program exploring a novel oral Factor XIIa inhibitor. With over two decades of expertise in serine protease inhibitor research, KalVista is positioned to address critical gaps in treatment for these conditions.

Arsanis, Inc. is a clinical-stage biopharmaceutical company headquartered in Waltham, Massachusetts, specializing in monoclonal antibody (mAb) immunotherapies for serious infectious diseases. Founded in 2010, Arsanis focuses on developing innovative therapies targeting various bacterial and viral pathogens. Its lead clinical program, ASN100, is currently in a Phase 2 trial aimed at preventing Staphylococcus aureus pneumonia in high-risk, mechanically ventilated patients. The company's preclinical pipeline includes mAbs directed against respiratory syncytial virus and Gram-negative bacteria, such as Klebsiella pneumoniae and Escherichia coli. Arsanis leverages advanced mAb discovery techniques to create a diverse range of therapeutic candidates with multiple mechanisms of action, addressing the urgent need for effective treatments in infectious disease management. The company also has research and preclinical development operations in Vienna, Austria, under Arsanis Biosciences GmbH.

CardioFocus, Inc. is a biotechnology company specializing in the development of innovative medical devices for the treatment of cardiac disorders, particularly atrial fibrillation. Founded in 1990 and headquartered in Marlborough, Massachusetts, the company has created advanced endoscopic ablation systems that enhance precision and control during medical procedures. Its flagship product, the HeartLight Endoscopic Ablation System, utilizes laser balloon technology to achieve consistent pulmonary vein isolation, crucial for managing paroxysmal atrial fibrillation. Additionally, the HeartLight Excalibur Balloon offers clinicians the ability to maintain stable contact with direct visualization for effective lesion creation, while the HeartLight X3 System provides a mode for controlled lesion development. CardioFocus aims to equip electrophysiologists with tools that improve treatment outcomes through enhanced visualization and customizable energy delivery, addressing the specific needs of patients undergoing ablation procedures.

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for eye diseases using its proprietary bioresorbable hydrogel platform technology. The company markets ReSure Sealant, a hydrogel ophthalmic wound sealant designed to protect corneal incisions after cataract surgery. Its lead product candidate, DEXTENZA, is an ophthalmic insert that has completed Phase III clinical trials for post-surgical ocular pain, inflammation, and allergic conjunctivitis, and is also being investigated for dry eye diseases. Additionally, Ocular Therapeutix is developing several other products, including OTX-TP, an intracanalicular travoprost insert for glaucoma, and OTX-TKI, an intravitreal implant for wet age-related macular degeneration, among others. The company has established a strategic collaboration with Regeneron Pharmaceuticals to leverage its hydrogel technology in combination with Regeneron's VEGF-targeting compounds for retinal diseases. Founded in 2006 and headquartered in Bedford, Massachusetts, Ocular Therapeutix aims to address unmet needs in ophthalmology through its advanced therapeutic solutions.

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for eye diseases using its proprietary bioresorbable hydrogel platform technology. The company markets ReSure Sealant, a hydrogel ophthalmic wound sealant designed to protect corneal incisions after cataract surgery. Its lead product candidate, DEXTENZA, is an ophthalmic insert that has completed Phase III clinical trials for post-surgical ocular pain, inflammation, and allergic conjunctivitis, and is also being investigated for dry eye diseases. Additionally, Ocular Therapeutix is developing several other products, including OTX-TP, an intracanalicular travoprost insert for glaucoma, and OTX-TKI, an intravitreal implant for wet age-related macular degeneration, among others. The company has established a strategic collaboration with Regeneron Pharmaceuticals to leverage its hydrogel technology in combination with Regeneron's VEGF-targeting compounds for retinal diseases. Founded in 2006 and headquartered in Bedford, Massachusetts, Ocular Therapeutix aims to address unmet needs in ophthalmology through its advanced therapeutic solutions.

Astria Therapeutics is a biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing innovative therapies for patients affected by rare allergic and immunological diseases. The company focuses on creating life-changing treatments, with its lead program, STAR-0215, being a monoclonal antibody designed to inhibit plasma kallikrein, currently in preclinical development for hereditary angioedema. Additionally, Astria is advancing STAR-0310, another monoclonal antibody, which targets the OX40 receptor and is also in preclinical development for atopic dermatitis, a condition characterized by impaired skin barrier function and significant itching. Through its targeted approach, Astria Therapeutics aims to address unmet medical needs in the field of immunology.

Good Start Genetics, Inc. is a molecular diagnostics company based in Cambridge, Massachusetts, founded in 2007. It specializes in genetic screening for inherited diseases, aiming to transform reproductive medicine by providing actionable information to physicians and patients. The company offers a range of services, including EmbryVu, a preimplantation genetic screening test designed to enhance in vitro fertilization outcomes by identifying suitable embryos for implantation. Additionally, Good Start Genetics provides a comprehensive array of genetic carrier screening tests through its GoodStart Select program, utilizing advanced next-generation DNA sequencing technology along with other established genetic screening methods. This focus on high carrier detection rates and commitment to customer care and genetic counseling positions the company as a leader in the field of pre-pregnancy genetic testing and diagnostics. As of August 2017, Good Start Genetics operates as a subsidiary of Invitae Corporation.

Logical Therapeutics, Inc., a biopharmaceutical company, engages in the development of drugs to treat diseases caused by or associated with excessive inflammation. Its products include LT-NS001, a non-steroidal anti-inflammatory drug for the treatment of chronic inflammatory conditions, such as osteoarthritis; Leptin, a hormone for the regulation of normal body mass and metabolism; and TNF, a hormone that promotes the proliferation of hepatocytes. The company was founded in 2005 and is based in Waltham, Massachusetts.

Astria Therapeutics is a biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing innovative therapies for patients affected by rare allergic and immunological diseases. The company focuses on creating life-changing treatments, with its lead program, STAR-0215, being a monoclonal antibody designed to inhibit plasma kallikrein, currently in preclinical development for hereditary angioedema. Additionally, Astria is advancing STAR-0310, another monoclonal antibody, which targets the OX40 receptor and is also in preclinical development for atopic dermatitis, a condition characterized by impaired skin barrier function and significant itching. Through its targeted approach, Astria Therapeutics aims to address unmet medical needs in the field of immunology.

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for eye diseases using its proprietary bioresorbable hydrogel platform technology. The company markets ReSure Sealant, a hydrogel ophthalmic wound sealant designed to protect corneal incisions after cataract surgery. Its lead product candidate, DEXTENZA, is an ophthalmic insert that has completed Phase III clinical trials for post-surgical ocular pain, inflammation, and allergic conjunctivitis, and is also being investigated for dry eye diseases. Additionally, Ocular Therapeutix is developing several other products, including OTX-TP, an intracanalicular travoprost insert for glaucoma, and OTX-TKI, an intravitreal implant for wet age-related macular degeneration, among others. The company has established a strategic collaboration with Regeneron Pharmaceuticals to leverage its hydrogel technology in combination with Regeneron's VEGF-targeting compounds for retinal diseases. Founded in 2006 and headquartered in Bedford, Massachusetts, Ocular Therapeutix aims to address unmet needs in ophthalmology through its advanced therapeutic solutions.

NKT Therapeutics, Inc. is a biotechnology company based in Waltham, Massachusetts, that specializes in developing therapeutics based on natural killer T (NKT) cells. Established in 2008, the company focuses on creating a pipeline of first-in-class NKT-based treatments targeting a range of conditions, including sickle cell disease, autoimmune and inflammatory diseases, cancer, asthma, and dermatitis. NKT Therapeutics utilizes a unique biotechnology platform that offers humanized monoclonal antibodies to selectively deplete iNKT cells, which are implicated in organ damage in preclinical models of sickle cell disease. By leveraging its expertise in the intersection of innate and adaptive immunity, NKT Therapeutics aims to provide innovative solutions for complex health challenges.

AlloCure, Inc. is a biotechnology company focused on developing cell therapies for kidney diseases and related conditions, including organ transplants and multi-organ injuries. Founded in 2006 and based in Burlington, Massachusetts, with additional operations in Salt Lake City, Utah, and Hamburg, Germany, AlloCure is dedicated to creating off-the-shelf biological therapies to address serious health issues affecting millions globally. The company's lead product, AC607, is a biologic therapy currently in development for acute kidney injury, with potential applications for other critical illnesses. AlloCure leverages proprietary technology utilizing processed cells derived from human bone marrow, founded by esteemed scientists Dr. Christof Westenfelder and Dr. Axel Zander, who have significant expertise in developing effective treatments for kidney diseases.

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for eye diseases using its proprietary bioresorbable hydrogel platform technology. The company markets ReSure Sealant, a hydrogel ophthalmic wound sealant designed to protect corneal incisions after cataract surgery. Its lead product candidate, DEXTENZA, is an ophthalmic insert that has completed Phase III clinical trials for post-surgical ocular pain, inflammation, and allergic conjunctivitis, and is also being investigated for dry eye diseases. Additionally, Ocular Therapeutix is developing several other products, including OTX-TP, an intracanalicular travoprost insert for glaucoma, and OTX-TKI, an intravitreal implant for wet age-related macular degeneration, among others. The company has established a strategic collaboration with Regeneron Pharmaceuticals to leverage its hydrogel technology in combination with Regeneron's VEGF-targeting compounds for retinal diseases. Founded in 2006 and headquartered in Bedford, Massachusetts, Ocular Therapeutix aims to address unmet needs in ophthalmology through its advanced therapeutic solutions.

Logical Therapeutics, Inc., a biopharmaceutical company, engages in the development of drugs to treat diseases caused by or associated with excessive inflammation. Its products include LT-NS001, a non-steroidal anti-inflammatory drug for the treatment of chronic inflammatory conditions, such as osteoarthritis; Leptin, a hormone for the regulation of normal body mass and metabolism; and TNF, a hormone that promotes the proliferation of hepatocytes. The company was founded in 2005 and is based in Waltham, Massachusetts.

Confluent Surgical develops products to address the need for surgical sealing and post-surgical adhesion prevention applications.The company provides DuraSeal, an adjunct to sutured dural repair during cranial surgeries to provide watertight closure. The company was founded in 1998 and is headquartered in Waltham, Massachusetts.

Alantos Pharmaceuticals is a biopharmaceutical company focused on the discovery and development of small molecule drugs targeting osteoarthritis, inflammation, and type II diabetes. Founded in 2002 and based in Cambridge, Massachusetts, the company specializes in creating innovative therapies, including Dipeptidyl and Peptidase IV inhibitors. Alantos also explores various tissue remodeling pathways to address conditions such as rheumatoid arthritis, liver fibrosis, cardiovascular issues, chronic wound healing, and cancer. Through its research and development efforts, Alantos Pharmaceuticals aims to advance treatment options for patients suffering from these chronic diseases.

Insulet Corporation, established in 2000, specializes in the development, manufacturing, and sale of insulin delivery systems for individuals with insulin-dependent diabetes. Its flagship product, the Omnipod System, comprises a self-adhesive, disposable, and tubeless device worn on the body for up to three days, along with a wireless, handheld personal diabetes manager. The company primarily sells its products through independent distributors, pharmacies, and directly to patients, with a presence in the United States, Canada, Europe, and the Middle East. Insulet's mission is to enhance the lives of people with diabetes by providing a user-friendly, pain-free, and automated insulin delivery solution.

Insulet Corporation, established in 2000, specializes in the development, manufacturing, and sale of insulin delivery systems for individuals with insulin-dependent diabetes. Its flagship product, the Omnipod System, comprises a self-adhesive, disposable, and tubeless device worn on the body for up to three days, along with a wireless, handheld personal diabetes manager. The company primarily sells its products through independent distributors, pharmacies, and directly to patients, with a presence in the United States, Canada, Europe, and the Middle East. Insulet's mission is to enhance the lives of people with diabetes by providing a user-friendly, pain-free, and automated insulin delivery solution.

Archemix Corp. is a biotechnology company based in Cambridge, Massachusetts, focused on the discovery, development, and commercialization of therapeutic aptamers for the prevention and treatment of both chronic and acute diseases. Established in 2000, Archemix is known for its aptamer product candidates, including ARC1779, which is aimed at treating thrombotic microangiopathies and is also relevant for use in carotid endarterectomy procedures. In addition to its work in these areas, the company is developing aptamer therapeutics targeting various conditions in the fields of cardiovascular health, hematology, and oncology.

CardioFocus, Inc. is a biotechnology company specializing in the development of innovative medical devices for the treatment of cardiac disorders, particularly atrial fibrillation. Founded in 1990 and headquartered in Marlborough, Massachusetts, the company has created advanced endoscopic ablation systems that enhance precision and control during medical procedures. Its flagship product, the HeartLight Endoscopic Ablation System, utilizes laser balloon technology to achieve consistent pulmonary vein isolation, crucial for managing paroxysmal atrial fibrillation. Additionally, the HeartLight Excalibur Balloon offers clinicians the ability to maintain stable contact with direct visualization for effective lesion creation, while the HeartLight X3 System provides a mode for controlled lesion development. CardioFocus aims to equip electrophysiologists with tools that improve treatment outcomes through enhanced visualization and customizable energy delivery, addressing the specific needs of patients undergoing ablation procedures.

Phase Forward is a prominent provider of integrated data management solutions specifically designed for clinical trials and drug safety. Founded in 1997 by Paul Bleicher, M.D., Ph.D., the company aimed to transition life sciences organizations from traditional paper-based methods to innovative, Internet-enabled solutions. Its flagship product, InForm, has significantly advanced electronic data capture, transforming how clinical data is collected, analyzed, and managed. Phase Forward's technology and global services facilitate the automation and integration of the clinical development process, encompassing study initiation, FDA submission, and post-marketing studies. The company's acquisition of Lincoln Technologies enhanced its capabilities, allowing it to offer comprehensive solutions for tracking and monitoring product efficacy and safety, ultimately leading to more efficient and cost-effective trial management. Prior to its acquisition by Oracle in 2010, Phase Forward was headquartered in Waltham, Massachusetts, with additional offices in the UK, Japan, France, and Australia.

CardioFocus, Inc. is a biotechnology company specializing in the development of innovative medical devices for the treatment of cardiac disorders, particularly atrial fibrillation. Founded in 1990 and headquartered in Marlborough, Massachusetts, the company has created advanced endoscopic ablation systems that enhance precision and control during medical procedures. Its flagship product, the HeartLight Endoscopic Ablation System, utilizes laser balloon technology to achieve consistent pulmonary vein isolation, crucial for managing paroxysmal atrial fibrillation. Additionally, the HeartLight Excalibur Balloon offers clinicians the ability to maintain stable contact with direct visualization for effective lesion creation, while the HeartLight X3 System provides a mode for controlled lesion development. CardioFocus aims to equip electrophysiologists with tools that improve treatment outcomes through enhanced visualization and customizable energy delivery, addressing the specific needs of patients undergoing ablation procedures.

GelTex Pharmaceuticals develops and markets non-absorbed polymer drugs that bind and eliminate targeted substances within the gastrointestinal tract. It also develops small-molecule pharmaceuticals consisting of novel polyamine analogues and metal chelators. Its focus areas include hyperphosphatemia, hypercholesterolemia, cancer, iron overload, and infectious diseases. GelTex Pharmaceutics is based in Waltham Massachusetts.